Monitoring T cell alloreactivity

Currently, immunosuppressive therapy in kidney transplant recipients is center-specific, protocol-driven, and adjusted according to functional or histological evaluation of the allograft and/or signs of drug toxicity or infection. As a result, a large fraction of patients are likely to receive too much or too little immunosuppression, exposing them to higher rates of infection, malignancy and drug toxicity, or increased risk of acute and chronic graft injury from rejection, respectively. To help clinicians individualize a immunosuppression regimens requires the development of assays able to reliably quantify and/or predict the magnitude of the recipient’s immune response towards the allograft.
Source: Transplantation Reviews - Category: Transplant Surgery Authors: Source Type: research